<DOC>
	<DOCNO>NCT02798250</DOCNO>
	<brief_summary>In previous study , investigator study pre-meal insulin bolus base estimate carbohydrate meal size would alleviate burden carbohydrate count without significant degradation postprandial glucose control . With strategy , patient would evaluate size meal term carbohydrate ( snack , regular , large large ) . It however important establish safety simplify meal bolus approach . The safety overestimate meal insulin bolus context closed-loop strategy need assess . For ethical reason , dual-hormone closed-loop test . Investigators hypothesize dual-hormone closed-loop overestimate meal size bolus increase time 4.0 mmol/L compare dual-hormone closed-loop adequately estimate meal size bolus .</brief_summary>
	<brief_title>Safety Overestimation Meal Insulin Bolus Context Dual-hormone Closed-loop Operation - Part 2</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Glucagon</mesh_term>
	<mesh_term>Glucagon-Like Peptide 1</mesh_term>
	<criteria>1 . Males females ≥ 18 year old . 2 . Clinical diagnosis type 1 diabetes least one year . 3 . The subject insulin pump therapy least 3 month currently use fast act insulin analog ( Lispro , Aspart Glulisine ) . 4 . Last ( less 3 month ) HbA1c ≤ 10 % . 5 . Currently use carbohydrate counting meal insulin dose strategy . 1 . Clinically significant microvascular complication : nephropathy ( estimate glomerular filtration rate 40 ml/min ) , neuropathy ( especially diagnose gastroparesis ) severe proliferative retinopathy judge investigator . 2 . Recent ( &lt; 3 month ) acute macrovascular event e.g . acute coronary syndrome cardiac surgery . 3 . Pregnancy . 4 . Severe hypoglycemic episode within 1 month screening . 5 . Agents affect gastric emptying ( Motilium® , Prandase® , Victoza® , Byetta® Symlin® ) well oral antidiabetic agent ( Metformin , SGLT2 inhibitor DPP4 inhibitor ) stable dose 3 month . Otherwise , medication acceptable keep stable entire protocol . 6 . Oral steroid unless patient present low stable dose ( e.g . 10 mg less prednisone per day physiological dos , less 35 mg/day , hydrocortisone Cortef® ) . Inhale steroid stable dose last month acceptable . 7 . Other serious medical illness likely interfere study participation ability complete trial judgment investigator ( e.g . unstable psychiatric condition ) . 8 . Failure comply team 's recommendation ( e.g . willing change pump parameter , follow algorithm 's suggestion , etc ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Type 1 diabetes</keyword>
	<keyword>Artificial pancreas</keyword>
	<keyword>Closed-loop system</keyword>
	<keyword>Postprandial glucose control</keyword>
	<keyword>Hypoglycemia</keyword>
	<keyword>Insulin</keyword>
	<keyword>Glucagon</keyword>
</DOC>